Guillaume J. Pegna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Guillaume J. Pegna has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Adel Kardosh
Knight Cancer Institute, Oregon Health and Science University, Portland, OR
1 shared publication - Alexander Ramos Guimarães
Brenden-Colson Center for Pancreatic Care, Knight Cancer Institute (OHSU), OR, Portland
1 shared publication Anna Jackson
Department of Medicine, Hematology and Medical Oncology, Oregon Health & Science University (OHSU), OR 97239, Portland
1 shared publicationAnne Fahlman
Department of Medicine, Hematology and Medical Oncology, Oregon Health & Science University (OHSU), OR 97239, Portland
1 shared publication- Brett C. Sheppard
Brenden-Colson Center for Pancreatic Care, Oregon Health and Science University, Portland, OR
1 shared publication - Brian Brinkerhoff
Department of Pathology, OHSU, OR 97239, Portland
1 shared publication
Latest Publications
- 8 October 2024
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (37) , 2915-2925
CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer
Asparagine synthetase (ASNS) catalyzes the biosynthesis of asparagine from aspartate and glutamine. Cells lacking ASNS, however, are auxotrophic for asparagine. Use of L-asparaginase to promote asparagine starvation in solid tumors with low ASNS levels, such as pancreatic ductal adenocarcinoma (PDAC), is a rationale treatment strategy. However, tumor cell resistance to L-asparaginase has limited its clinical utility. Our preclinical studies show that RAS/MAPK signaling circumvents L-asparaginase-induced tumor killing, but L-asparaginase and MEK inhibition potentiated tumor killing; suggesting that this combination may provide meaningful clinical benefit to patients with PDAC. This Phase I trial (NCT05034627) will evaluate the safety and tolerability of the MEK inhibitor, cobimetinib, in combination with pegylated L-asparaginase, L calaspargase pegol-mknl, in patients with locally-advanced or metastatic PDAC.
- 8 October 2024
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (37) , 2915-2925
CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer
Asparagine synthetase (ASNS) catalyzes the biosynthesis of asparagine from aspartate and glutamine. Cells lacking ASNS, however, are auxotrophic for asparagine. Use of L-asparaginase to promote asparagine starvation in solid tumors with low ASNS levels, such as pancreatic ductal adenocarcinoma (PDAC), is a rationale treatment strategy. However, tumor cell resistance to L-asparaginase has limited its clinical utility. Our preclinical studies show that RAS/MAPK signaling circumvents L-asparaginase-induced tumor killing, but L-asparaginase and MEK inhibition potentiated tumor killing; suggesting that this combination may provide meaningful clinical benefit to patients with PDAC. This Phase I trial (NCT05034627) will evaluate the safety and tolerability of the MEK inhibitor, cobimetinib, in combination with pegylated L-asparaginase, L calaspargase pegol-mknl, in patients with locally-advanced or metastatic PDAC.
- 1 April 2016
- Published by Elsevier in Biomaterials
- Vol. 84, 42-53
Fibrin matrices enhance the transplant and efficacy of cytotoxic stem cell therapy for post-surgical cancer
- 1 April 2016
- Published by Elsevier in Biomaterials
- Vol. 84, 42-53
Fibrin matrices enhance the transplant and efficacy of cytotoxic stem cell therapy for post-surgical cancer